^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Padcev (enfortumab vedotin) (Microtubule inhibitor, Nectin-4-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
04/25/2023
Excerpt:
Bladder Cancer….Cisplatin ineligible, first-line therapy for locally advanced or metastatic disease….Preferred regimen:...pembrolizumab and enfortumab vedotin-ejfv
